Page last updated: 2024-11-06

benzylvanillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzylvanillin is a synthetic flavoring agent with a strong vanilla aroma. It is produced by the reaction of vanillin with benzyl chloride in the presence of a base. Benzylvanillin is commonly used in food and beverage products, such as ice cream, candy, and baked goods, to enhance the flavor and aroma of vanilla. The compound is also used in perfumes and cosmetics. Benzylvanillin is generally considered safe for human consumption, but some individuals may experience allergic reactions. Research on benzylvanillin has focused on its potential use as a flavoring agent, its safety profile, and its impact on the human sensory system.'

benzylvanillin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID75506
CHEMBL ID3278089
SCHEMBL ID161066
MeSH IDM0281385

Synonyms (59)

Synonym
EN300-15514
BB 0243318
4-benzyloxy-3-methoxy-benzaldehyde
benzaldehyde, 4-(benzyloxy)-3-methoxy-
benzaldehyde, 3-methoxy-4-(phenylmethoxy)-
nsc-44876
nsc44876
nsc22599
nsc-22599
2426-87-1
OPREA1_669509
vanillin benzyl ether
nsc-208757
nsc208757
4-benzyloxy-3-methoxybenzaldehyde, 98%
STK187550
4-(benzyloxy)-3-methoxybenzaldehyde
o-benzylvanillin
OPREA1_505077
3-methoxy-4-phenylmethoxybenzaldehyde
AKOS000119693
3-methoxy-4-(phenylmethoxy)benzaldehyde
ST005515
BBL007567
B3599
4-benzyloxy-3-methoxybenzaldehyde
nsc 22599
nsc 44876
nsc 208757
5knc2tsw9g ,
unii-5knc2tsw9g
ai3-36398
einecs 219-379-0
benzylvanillin
FT-0634267
PS-3806
AE-641/00776056
CHEMBL3278089
3-methoxy-4-(phenylmethoxy) benzaldehyde
3-methoxy-4-(phenylmethyloxy)benzaldehyde
4-(benzyloxy)-3-methoxy-benzaldehyde
4-benzyloxy-3-methoxy benzaldehyde
3-methoxy-4-benzyloxybenzaldehyde
3-methoxy-4-benzyloxy benzaldehyde
SCHEMBL161066
W-206883
STR05288
benzaldehyde, 4-benzyloxy-5-methoxy-
4-o-benzylvanillin
3-methoxy-4-(benzyloxy)benzaldehyde
DTXSID80178958
mfcd00003365
3-methoxy-4-(n-piperidinomethyl oxo)-benzaldelyde
SY048593
Z26337248
AMY15223
CS-W012776
4-benzyloxy-3-methoxybenzaldehyde (vanillin benzyl ether)
Q27262489

Research Excerpts

Effects

ExcerptReferenceRelevance
"The benzylvanillin alone (Bn1) has weak anticancer activity even after it was combined with the benzimidazole (2MP), but after addition of another benzylvanillin structure (2XP), stronger activity was observed."( Conjugation of benzylvanillin and benzimidazole structure improves DNA binding with enhanced antileukemic properties.
Abdul Majid, AM; Al-Mudaris, ZA; Al-Mudarris, BA; Chen, SH; Jamal Din, SK; Ji, D; Liang, PH; Majid, AS; Osman, H, 2013
)
1.22
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1149894Hypolipidemic activity in CFY Sprague-Dawley rat assessed as liver lipid per gm of liver at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149890Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum cholesterol level at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149892Toxicity in CFY Sprague-Dawley rat assessed as body weight gain at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149891Hypolipidemic activity in CFY Sprague-Dawley rat assessed as serum triglyceride level at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
AID1149893Toxicity in CFY Sprague-Dawley rat assessed as relative liver weight at 0.25% dietary level administered for 7 days relative to control1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Hypolipidemic analogues of ethyl 4-benzyloxybenzoate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's2 (33.33)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.60 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]